These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 24517426)
1. Transplantation tolerance: from theory to clinic. Fuchs EJ Immunol Rev; 2014 Mar; 258(1):64-79. PubMed ID: 24517426 [TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713 [TBL] [Abstract][Full Text] [Related]
4. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527 [TBL] [Abstract][Full Text] [Related]
5. A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance. Johnstone BH; Messner F; Brandacher G; Woods EJ Front Immunol; 2021; 12():622604. PubMed ID: 33732244 [TBL] [Abstract][Full Text] [Related]
6. Facilitating cells as a venue to establish mixed chimerism and tolerance. Jacquet EG; Schanie CL; Fugier-Vivier I; Willer SS; Ildstad ST Pediatr Transplant; 2003 Oct; 7(5):348-57. PubMed ID: 14738294 [TBL] [Abstract][Full Text] [Related]
7. Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model. Graves SS; Mathes DW; Georges GE; Kuhr CS; Chang J; Butts TM; Storb R Transplantation; 2012 Sep; 94(6):562-8. PubMed ID: 22929594 [TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation. Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257 [TBL] [Abstract][Full Text] [Related]
9. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388 [TBL] [Abstract][Full Text] [Related]
10. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
11. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism. Wang J; Li L; Xu M; Rong R; Zhu T Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211 [TBL] [Abstract][Full Text] [Related]
12. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972 [TBL] [Abstract][Full Text] [Related]
14. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882 [TBL] [Abstract][Full Text] [Related]
15. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Johnson BD; Truitt RL Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664 [TBL] [Abstract][Full Text] [Related]
16. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. Shimoni A; Nagler A Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195 [TBL] [Abstract][Full Text] [Related]
17. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701 [TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Itakura S; Asari S; Rawson J; Ito T; Todorov I; Liu CP; Sasaki N; Kandeel F; Mullen Y Am J Transplant; 2007 Feb; 7(2):336-46. PubMed ID: 17283484 [TBL] [Abstract][Full Text] [Related]
19. Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: The importance of durable chimerism. Leventhal JR; Ildstad ST Hum Immunol; 2018 May; 79(5):272-276. PubMed ID: 29409743 [TBL] [Abstract][Full Text] [Related]
20. Chimerism-based tolerance in organ transplantation: preclinical and clinical studies. Oura T; Cosimi AB; Kawai T Clin Exp Immunol; 2017 Aug; 189(2):190-196. PubMed ID: 28369830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]